Supplementary Figure 3 from Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation
crossref（2023）
摘要
PDF file - 52KB, MEHD7945A is more potent than the combination of cetuximab and erlotinib
查看译文
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要